Rahul Bhargava: Late-Breaking ASH 2025 Highlight
Rahul Bhargava, Director and Head of Hematology, Hematoncology and Stem Cell Transplant at Fortis Health Care , shared a post from ASH on LinkedIn:
“Late-Breaking ASH 2025 Highlight
MajesTEC-3: Teclistamab + Daratumumab (Tec-Dara) changing the game in Relapsed/Refractory Multiple Myeloma
One curve says it all — HR 0.17, 83.3% 3-year OS, median not reached!
We are witnessing the dawn of a new era where bispecifics and immune-based combinations are pushing survival boundaries beyond imagination.
The Tec-Dara regimen not only doubles durability compared to DPd/DVd but also offers hope for long-term disease control — a vision once unimaginable in RRMM.
The best part? These cutting-edge therapies are now available at the Fortis Advanced Center for Myeloma and Lymphoma Research — bringing the world’s most advanced science straight to our patients.
Truly unbelievable progress — the future of myeloma treatment is being rewritten.”
More posts on Hemostasis Today.
-
Sep 25, 2026, 16:01Mostafa Hammam: When aPTT Correction Is Not the End
-
Sep 25, 2026, 15:50Adam Boruchov: Registration Is Open For The 2026 New England Hematologic Diseases Symposium
-
Sep 25, 2026, 15:23Bringing Hope and Treatment Access to Morocco’s Hemophilia Community – World Federation of Hemophilia
-
Sep 25, 2026, 15:22Alejandro González Veliz: Targeting Atherosclerosis Before the First Event
-
Sep 25, 2026, 15:00Sarah Richardson: Finding Strength Through Bleeding Disorders Advocacy
-
Sep 25, 2026, 14:54James Fildes: Modeling Device Related Thrombosis in Multi Organ Systems
-
Sep 25, 2026, 14:51Platelet Metabolic Reprogramming: How Cellular Energy Drives Thrombosis
-
Sep 25, 2026, 14:46Thomas Maxwell: From Hemophilia Shame to Strength – Walking for Bleeding Disorders
-
Sep 25, 2026, 14:35Sarita Rani Jaiswal: Sharing Basic Science Insights at EBMT HWP 2026